Intravenous antibiotic therapy represents a considerable expense to hospital pharmacy budgets ; however, when evaluating the cost of these therapies one needs to look beyond acquisition cost and consider the total « process » cost of treatment.
These additional costs include the personnel time and the materials required for drug preparation and administration, maintenance of intravenous access, waste disposal, and therapeutic drug monitoring.
This paper provides an examination of the daily process costs of intravenous therapy with cefazolin, cefotaxime, ceftazidime, once-daily ceftriaxone, cefuroxime, or aminoglycoside (tobramycin or gentamicin) combination therapy, where the aminoglycoside is given once daily or in divided doses.
This analysis demonstrates that the costs associated with drug preparation and administration can equal or exceed drug acquisition costs and are highly dependent on dosing frequency.
On this basis, ceftriaxone, at $52.21, is the least expensive of these antibiotic regimens in terms of total daily process cost, followed by the remaining cephalosporins at $53.29 to $94.57, aminoglycoside once-daily combinations at $93.44 to $99.65, and aminoglycoside multidose combinations at $103.26 to $111.42, respectively (values are given in constant 1995 Canadian dollars). (...)
Mots-clés Pascal : Antibiotique, Antibactérien, Voie parentérale, Céphalosporine dérivé, Aminoglycoside, Chimiothérapie, Traitement, Infection, Homme, Voie intraveineuse, Dose journalière unique, Dose répétée, Coût, Economie santé, Canada, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Antibiotic, Antibacterial agent, Parenteral administration, Cephalosporin derivatives, Aminoglycoside, Chemotherapy, Treatment, Infection, Human, Intravenous administration, Single daily dose, Multiple dose, Costs, Health economy, Canada, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0441590
Code Inist : 002B02S02. Création : 10/04/1997.